HHLR Advisors’s Century Therapeutics IPSC Stock Holding History

HHLR Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-496,624	Closed	-$2.55M	–	73
2022 Q4	$2.55M	Sell	496,624 -117,471	-19%	-$1.11M	0.05%	55
2022 Q3	$6.07M	Hold	614,095	–	–	0.16%	42
2022 Q2	$5.16M	Hold	614,095	–	–	0.11%	44
2022 Q1	$7.73M	Hold	614,095	–	–	0.16%	36
2021 Q4	$9.74M	Hold	614,095	–	–	0.15%	50
2021 Q3	$15.5M	Hold	614,095	–	–	0.2%	52
2021 Q2	$18M	Buy	+614,095	New	+$15.6M	0.19%	54

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HHLR Advisors's IPSC Position: Q1 2023 in Review

HHLR Advisors sold out of Century Therapeutics (IPSC) in Q1 2023, closing a stake of 496,624 shares — an estimated $2.55M sold.

HHLR Advisors first reported a position in IPSC in Q2 2021 and held it in 7 quarters. The position peaked at $18M in Q2 2021. 63 funds tracked by Wall St. Rank hold IPSC as of Q1 2023.

HHLR Advisors reported no remaining Century Therapeutics position as of Q1 2023 after selling out during the quarter.
HHLR Advisors sold 496,624 Century Therapeutics shares in Q1 2023, an estimated $2.55M.
HHLR Advisors first reported a position in Century Therapeutics in Q2 2021 and held it in 7 quarters.
HHLR Advisors's Century Therapeutics position peaked at $18M in Q2 2021.
63 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2023.

Based on HHLR Advisors's 13F filing for Q1 2023, filed 15 May 2023.